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Abstract
Schizophrenia is characterized by deficits in cognition as well as visual perception. There have,
however, been few magnetic resonance imaging (MRI) studies of the occipital lobe as an
anatomically defined region of interest in schizophrenia. To examine whether or not patients with
chronic schizophrenia show occipital lobe volume abnormalities, we measured gray matter volumes
for both the primary visual area (PVA) and the visual association areas (VAA) using MRI based
neuroanatomical landmarks and three-dimensional information. PVA and VAA gray matter volumes
were measured using high-spatial resolution MRI in 25 male patients diagnosed with chronic
schizophrenia and in 28 male normal controls. Chronic schizophrenia patients showed reduced
bilateral VAA gray matter volume (11%), compared with normal controls, whereas patients showed
no group difference in PVA gray matter volume. These results suggest that reduced bilateral VAA
may be a neurobiological substrate of some of the deficits observed in early visual processing in
schizophrenia.
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Introduction
Schizophrenia is characterized by deficits in cognition as well as visual perception. (O’Donnell
et al., 1996; Tek et al., 2002). Deficits in early visual processing have been repeatedly reported
(Doniger et al., 2002; Keri et al., 2004; Butler et al., 2001, 2005), and recent
electroencephalographic (EEG) studies provide further evidence for deficits in early visual
processing in schizophrenia (Doniger et al., 2002; Butler et al., 2001, 2005). With respect to
clinical symptoms, patients with schizophrenia sometimes evince visual hallucinations, which
are associated with activity in the visual association cortex (Silbersweig et al., 1995). Of note
here, Weiss and Heckers (1999) noted that the neural systems involved in the perception of
hallucinations appears to involve the same modality-specific cerebral structures as are involved
in normal perception. Recently, Molina et al. (2005) reported that clozapine increased occipital
lobe metabolism including primary and association visual areas, and that the metabolic increase
was associated with improvement of positive symptoms. Our own laboratory has documented
that visual gestalt stimuli lead to abnormal gamma band EEG activity over the occipital lobe
in schizophrenia, and that this abnormal gamma activity is associated with visual hallucinations
(Spencer et al., 2003, 2004). It thus seems likely that the occipital lobe is involved in some
aspects of the pathophysiology of schizophrenia.
Magnetic resonance imaging (MRI) has been helpful in revealing subtle structural brain
abnormalities in schizophrenia (see reviews in McCarley et al., 1999; Shenton et al., 2001)
although the small number of studies that have measured occipital lobe have shown mixed
findings. Five studies reported volume reduction in the occipital lobe in schizophrenia
(Zipursky et al., 1992; Andreasen et al., 1994; Bilder et al., 1994, 1999; Davatzikos et al.,
2005). However, differences in methodology and Regions of Interest (ROI) definition may
have accounted for some of the disparate results. In terms of neuroanatomically defined studies
of occipital lobe, Zipursky et al. (1992) used seven axial MRI sections for segmentation and
found significant gray matter volume reduction in the occipital lobe in patients. On the other
hand, Goldstein et al. (1999). reported no group differences between patients with
schizophrenia and controls in the occipital lobe. For voxel-based morphometric (VBM) studies,
Davatzikos et al. (2005) reported reduced gray matter in occipital association areas in patients
with schizophrenia, although there have also been negative findings reported using VBM (e.g.,
Kubicki et al., 2002; Giuliania et al., 2005).
Based on direct comparisons of VBM and ROI, we (Kubicki et al., 2002) and Giuliania et al.
(2005) concluded that VBM is useful for hypothesis generation, but that its anatomical warping
and density-based methodology often lead to failure to detect abnormalities seen using ROI
analysis. In the present study we adopted a neuroanatomically defined and manually delineated
ROI method to evaluate occipital lobe ROI.
One possible reason for the small number of neuroanatomically defined ROI studies may be
due to difficulties in defining occipital lobe boundaries. The boundary between the occipital
lobe and parietal lobe, the parietooccipital sulcus (POS), clearly separates the two lobes on the
medial surface (Duvernoy, 1991). However, on the lateral surface, these two lobes are usually
divided with a (theoretical) line starting at the parietooccipital fissure and extending to the
temporo-occipital incisure (Duvernoy, 1991). In the present study, we used three-dimensional
information to provide reliable measures of the occipital lobe with a software package for
medical image analysis [3D slicer, http://www.slicer.org] on a workstation.
For ROI studies, it is important to separate gray and white matter in the analysis. This approach
can improve the detection of subtle gray matter volume differences between groups, since white
matter volume may be relatively intact as reported in several MRI studies of frontal and
temporal lobes in schizophrenia (e.g., Gur et al., 2000; Hirayasu et al., 2001). Thus, in the
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present study, we used a fully-automated segmentation program (Wells et al., 1996) to classify
tissue into gray matter, white matter, and cerebral spinal fluid (CSF). Finally, consideration
must be given to linking neuroanatomically defined ROI to functional divisions whenever
possible (e.g., delineation for Heschl’s gyrus, the locus of primary auditory cortex [Hirayasu
et al., 2000]). For the occipital lobe, the cytoarchitecture changes abruptly at the border between
Brodmann areas 17 and 18, with especially prominent changes in layer IV, which becomes
thinner and less differentiated in area 18 than in area 17 (Amunts et al., 2000). Although
structural MRI cannot identify this border, functional neuroimaging studies have reported that
the primary visual area in humans is distributed approximately one gyrus above and below the
calcarine fissure (Tootell et al., 1996; Van Essen &Drury 1997). We therefore decided to use
this ROI definition to delineate these regions; for convenience we will refer to the (mainly)
primary visual area as PVA and the (mainly) visual association area as VAA, comprising the
non-PVA portions of the occipital lobe. Our using designations other than Brodmann areas
and those in use in anatomical studies will also serve to indicate the tentative functional
identification of PVA and VAA.
The principal aim of this study was to measure PVA and VAA gray matter volumes in chronic
schizophrenia and normal comparison subjects, using high spatial resolution MRI (0.9375-
mm3 voxels in resampled slices) and three-dimensional information, in order to provide more
reliable measurement of these brain regions, as well as to determine whether or not there are
differences between groups. We also investigated associations between clinical symptoms and
gray matter volumes of PVA and VAA in the patient sample, where we predicted that increased
severity of visual hallucinations would be significantly associated with reduced occipital gray
matter volumes.
Subjects and Methods
Subjects
Twenty-five male patients with chronic schizophrenia and 28 male normal control subjects
participated in this study. Subjects included 2 new subjects and 49 subjects common (23
patients and 28 normal controls) to our most recently published ROI study in chronic
schizophrenia (Onitsuka et al., 2004) (the study reported reduced left middle inferior temporal
and bilateral inferior temporal gyri gray matter volumes in schizophrenia). After a complete
description of the study, written informed consent was obtained from all participants. The age
range for inclusion was 20 to 55 years. Subjects were included if they had no history of: 1)
neurologic illness or major head trauma; 2) electroconvulsive therapy; 3) alcohol or drug
dependence; or 4) alcohol and drug abuse within the past five years. Table 1 shows
demographic and clinical characteristics of study groups.
Normal control subjects were recruited through newspaper advertisement and screened using
the Structured Clinical Interview (SCID non-patient edition) by trained interviewers (MES,
MF). No control subjects had an Axis-I psychiatric disorder or a first-degree relative with Axis-
I psychiatric disorder. The mean age of the normal control group was 42.0 ± 7.5 (mean ± SD)
years (range: 28-55).
All patients were diagnosed with schizophrenia based on DSM-IV criteria, using information
from the Structured Clinical Interview for DSM-III-R by the same trained interviewers.
Patients were recruited from the VA Boston Healthcare System, Brockton Division. All
patients were receiving neuroleptic medication, with a mean daily dose equivalent to 497 ±
258 mg of chlorpromazine [typical (9 of the 25 patients), atypical (15), or both (1)]. The mean
age of patients was 42.6 ± 8.4 years (range: 29–55), their mean age at symptom onset was 22.7
± 4.1 years, and their mean duration of illness was 19.9 ± 9.6 years. The Scale for the
Assessment of Positive Symptoms (SAPS) (Andreasen, 1984) and the Scale for the Assessment
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of Negative Symptoms (SANS) (Andreasen, 1981) were administered to patients. Mean ± SD
SAPS and SANS scores were 8.8 ± 4.1 and 12.3 ± 3.8, respectively. For the SAPS, visual
hallucination scores (0=none, 5=severe) were available in sixteen of the twenty-five patients.
Mean ± SD score was 1.3 ± 1.5 (range 0–4).
Handedness was assessed using the Edinburgh inventory. Socioeconomic status (SES) of
subjects and parental SES were measured by the Hollingshead two-factor index (1=highest,
5=lowest). All subjects were given the WAIS-R information subscale as an estimate of gross
fund of information. T-tests were used to assess group differences in age, handedness score,
SES, parental SES and WAIS-R information subscale scores. There were no significant group
differences in age, handedness score, parental SES or WAIS-R information subscale (see Table
1). Patients with schizophrenia showed significantly lower SES than normal control subjects
(t[51]=−7.82, p<0.001), consistent with reduced functioning due to the disorder.
MRI Procedures and Definition of Occipital Lobe
The acquisition was done with a 1.5-Tesla General Electric scanner (GE Medical Systems,
Milwaukee) at the Brigham and Women’s Hospital in Boston. The protocol followed that of
our previous publication (Onitsuka et al., 2004).
Figure 1 shows the medial and lateral view of the three-dimensional reconstruction of the
occipital lobe. The following steps were used to define the occipital lobe. First, the
parietooccipital sulcus (POS) was identified on the midsagittal plane for each hemisphere.
Second, the anterior tip of the POS was identified, as well as the posterior tip of the POS that
corresponds to the parietooccipital fissure (see figure 1). The occipital lobe was defined as
beginning at one slice posterior to the plane that contains the anterior tip of the POS, identified
on the midsagittal plane, and ending in the last slice in the coronal plane, including the posterior
tip of occipital lobe. For the medial surface, the boundary between the parietal and occipital
lobe was the POS. For the lateral surface, the rater (TO) drew a guideline connecting the
parietooccipital fissure and the superior temporal sulcus, or anterior occipital sulcus, on the
first, beginning slice of occipital lobe. This guideline was defined as the boundary between the
parietal and occipital lobe for the lateral surface. This guideline was seen as a point on each
coronal image (see Figure 2c). The parietal and occipital lobe were divided operationally by
extending the guideline across the tissue bridge of white matter, horizontally and medially up
to the intraparietal sulcus (see Figure 2 c&d).
The primary visual area (PVA) was defined as the area between one gyrus above the calcarine
fissure and one gyrus below the sulcus on each coronal image. The rater drew two guidelines
at 3–5 slices laterally from the medial surface to determine the gyri above and below calcarine
fissure (see Figure 2b). The lines were drawn extending the sulcal course across the tissue
bridge of white matter. These guidelines were seen as points on each coronal image and the
rater delineated the primary visual area referring to the lines (see Figure 2c). Manual drawings
of the ROIs were then performed on the realigned and resampled coronal slices (see Figure
2d).
Interrater reliability was computed for the ROIs by 3 independent raters (TO, NK, and SSD),
who were blinded to diagnostic group membership. Six cases were selected randomly for
interrater reliability. Three raters measured the occipital lobe on every third slice. An intraclass
correlation coefficient was used to compute interrater reliability. For the three raters, the
intraclass correlations were: 0.93 for the left PVA, 0.90 for the right PVA, 0.98 for the left
VAA, 0.98 for the right VAA.
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Statistical Analyses
A T-test was used to assess group differences in Total ICC. There was no significant group
difference in total ICC (t[51]=1.52, p=0.13). However, to correct for variations in brain size,
we used relative volumes of PVA and VAA computed as [(absolute volume)/(ICC)] × 100 for
ROI analysis. To examine whether or not the ROI volumes were normally distributed, Shipiro-
Wilk tests (Shapiro&Wilk, 1965) were performed for each ROI in both groups. To determine
whether or not certain ROIs were more affected than other ROIs, the ROI volumes were first
converted to Z-scores so that all the ROIs would be on the same scale. The mean and standard
deviation of the control group were used to calculate the Z-scores. For ROI analysis, the
standardized scores were submitted to a mixed model repeated measure ANOVA with group
(schizophrenia or controls) as a between-subjects factor, and hemisphere (left or right) and
subdivision (PVA or VAA) as within-subjects factors.
Exploratory analyses were performed, using Spearman’s rho, to explore the relationship
between volumes for each ROI, and demographic data, the SAPS and SANS total scores, as
well as for SAPS visual hallucination scores. Here, all correlations were considered significant
only if they reached p≤0.05 (two-tailed), for both relative and absolute volumes.
Results
Volume of occipital lobe
Table 2 shows absolute and relative occipital lobe volumes of patients with schizophrenia and
normal controls. For the 3-factor (2 groups × 2 sides × 2 subdivisions) ANOVA of standardized
ROI values (Z-scores), there was a significant main effect of subdivision (F[1,51]=4.08,
p=0.05, while there was no significant main effect of hemisphere (F[1,51]=0.06, p=0.81), or
group (F[1,51]=2.16, p=0.15). There was also no significant hemisphere-by-subdivision-by-
group interaction (F[1,51]=0.06, p=0.94). However, there was a significant subdivision-by-
group interaction (F[1,51]=4.08, p=0.05) but no significant hemisphere-by-group (F[1,51]
=0.06, p=0.81) or hemisphere-by-subdivision (F[1,51]=0.06, p=0.94) interactions.
To further delineate the subdivision-by-group significant interaction, follow up ANOVA was
performed for each subdivision. For PVA, there was no significant main effect of group (F
[1,51]=0.09, p=0.77) or hemisphere (F[1,51]=0.07, p=0.79), and no significant hemisphere-
by-group interaction (F[1,51]=0.07, p=0.79). These results suggest that there is no group
difference in PVA bilaterally.
For VAA, there was a significant main effect of group (F[1,51]=5.05, p=0.03) without a
significant main effect of hemisphere (F[1,51]=0.02, p=0.89) or a significant hemisphere-by-
group interaction (F[1,51]=0.02, p=0.89), indicating that patients showed bilateral VAA
reduction compared with normal controls. The percentages of relative VAA reduction of
patients were 11.4 % for the left and 10.7 % for the right.
Correlations between volume of occipital lobe and demographic/clinical measurements
In normal controls, age, parental SES, SES, handedness and WAIS-R information subscale
scores did not correlate significantly with occipital lobe volume (−0.351≤rho≤0.301,
0.07≤p≤0.98), with the exception of a significant negative correlation between SES and right
PVA volume (rho=−0.522, p=0.004 for absolute; rho=−0.525, p=0.004 for relative). In patients
with schizophrenia, age, SES, parental SES, WAIS-R information subscale scores, duration of
illness, and dose (chlorpromazine equivalent) of medication did not correlate significantly with
occipital lobe volume (−0.383≤rho≤0.360, 0.07≤p≤0.98), with the exception of a significant
positive correlation between WAIS-R information subscale score and left PVA volume
(rho=0.484, p=0.01 for absolute; rho=0.464, p=0.02 for relative)
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In examining the relationships between occipital lobe volume and psychopathology measures,
there were no significant correlations between ROIs and SAPS or SANS total scores
(−0.386≤rho≤0.097, 0.07≤p≤0.93). For SAPS visual hallucination scores, we found no
significant correlations between the scores and left PVA volumes or left or right VAA volumes
(−0.251≤rho≤0.074, 0.35≤p≤0.97). However there was a significant negative correlation
between right PVA volumes and visual hallucination scores (rho=−0.632, p=0.009 for absolute;
rho=−0.617, p=0.011 for relative). Because of the results of Spencer et al. (2003, 2004), t-tests
were used for additional (exploratory) analyses of ROI volume differences between the 9
patients with and the 7 patients without visual hallucinations. Of note here, there was a
significant group difference in right PVA gray matter volume (t[14]= −2.32, p=0.04), although
there were no significant differences in the other ROIs (−1.15≤t[14] ≤ −0.08, 0.27≤p≤0.94).
For differences in demographic/clinical measurements between patients with and without
visual hallucinations, there were no significant subgroup differences in chlorpromazine
equivalent (t[14]= −0.12, p=0.90), age (t[14]=−0.03, p=0.97), age at symptom onset (t[14]
=1.48, p=0.16), duration of illness (t[14]=−0.80, p=0.44), SES (t[14]= −0.38, p=0.71), parental
SES (t[14]=0.63, p=0.54) or handedness (t[14]=1.23, p=0.24).
Discussion
The current study examined PVA and VAA gray matter volumes and investigated correlations
between ROI volumes and clinical symptoms. For PVA gray matter volume, there was no
significant group difference, while patients with schizophrenia showed significant VAA gray
matter volume reduction, bilaterally, compared with healthy controls.
There are a small number of previous structural MRI studies of occipital lobe in schizophrenia.
Goldstein et al. (1999), for example, used a semi-automated method of cortical parcellation to
measure 48 topography defined brain regions of the entire neocortex and found no difference
in occipital lobe gray matter volume between 29 patients (12 females) and 26 control subjects
(14 females), although they reported the results of both genders as one group. In contrast,
Andreasen et al. (1994) used an automated atlas-based dissection of specific regions without
separation for gray and white matter. They reported a significant difference in occipital brain
tissue volume between 36 male patients and 48 male controls, while there was no group
difference in female subjects; thus gender differences in the manifestation of schizophrenia
may account for the reported discrepancies in findings. In addition, differences in ROI
definition and methodology may also account for the reported discrepancies. For example,
Zipursky et al. (1992) used seven axial MRI sections for segmentation and found significant
gray matter volume reduction in the occipital lobe in patients. More recently, Quarantelli et al.
(2002) used their own automated segmentation method of major brain structures according to
the Talairach atlas and found no group differences in occipital lobe between controls and
patients with schizophrenia. However a recent VBM study (Davatzikos et al., 2005) reported
reduced gray matter in occipital lobe areas in patients with schizophrenia
Another possible reason for inconsistent findings is that occipital lobe volume reduction may
be just at the threshold for MRI detection, and hence whether statistical significance is found
may depend heavily on the subject group evaluated. As reviewed by Shenton et al. (2001), the
left superior temporal gyrus (STG) gray matter reduction is the most frequently reported MRI
finding in patients with schizophrenia; thus the left STG reduction is thought to be most
common affected region across individuals in schizophrenia, while occipital lobe reduction is
relatively less common across individuals. Random variation in subjects may therefore account
for inconsistent findings in the occipital lobe in schizophrenia.
The current study suggests that the primary visual area was relatively intact in schizophrenia
compared to the association area. Pearlson et al. (1996) highlights the importance of structural
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abnormalities in schizophrenia in heteromodal association cortex. Our current finding that PVA
did not differ between groups may partially support this hypothesis since our PVA is mainly
unimodal primary sensory cortex. In a postmortem study by Selemon et al. (1995), these
investigators found neuronal density increase in pyramidal layers III and V, with a trend-level
cortical thickness reduction in Brodmann area 17 in patients with schizophrenia. Of note here,
our current finding may not conflict completely with their finding since cortical thickness
reduction was trend-level and it remains unclear how cortical thickness relates to cortical gray
matter volume.
With respect to clinical correlations, although exploratory, increased severity of visual
hallucinations was significantly associated with smaller right PVA volumes in patients with
schizophrenia. Of further note, a recent case report of a patient with brain infarction in the right
medial occipital lesion showed visual hallucinations (Beniczky et al., 2002). Moreover, there
was a case report that a patient with brain infarction in the region of the calcarine fissure showed
visual hallucinations (Merabet et al., 2003). Although there were no significant group
differences observed for PVA gray matter volume, t-tests comparing the 9 patients with and
the 7 patients without visual hallucinations showed a significant group difference in right PVA
gray matter volume. To the best of our knowledge, our study is the first structural MRI study
that indicates a significant association between the occipital lobe and visual hallucinations in
patients with schizophrenia. In conjunction with findings of case reports and our results, the
PVA might be crucial for visual hallucinations. However, this exploratory finding warrants
confirmation in a larger sample.
In reviewing the current study, it is important to point out several possible limitations. First,
the current study cannot answer the question of whether the volume reduction observed is
associated with progressive in the peri- and/or post-onset course of illness, or whether it is
neurodevelopmental in origin, or perhaps a combination of both. It will thus be important to
investigate whether VAA gray matter volume undergoes a progressive decrease over a period
of 1.5 years following first hospitalization, as we have found for superior temporal gyrus
(Kasai et al., 2002). Second, the current study also did not allow us to exclude the effect of
chronic treatment with neuroleptic medication on VAA gray matter abnormalities in patients
(although no volume measure correlated with neuroleptic dosage), nor did we demonstrate
specificity to schizophrenic psychosis, as we did not include another psychosis group. It will
thus be important to investigate whether VAA abnormality is observed or not in patients with
schizophrenia and affective psychosis at their first hospitalization, with minimal or no
medication history. Third, this study does not provide the answer as to whether female patients
show gray matter volume abnormality of VAA or not, since this study did not include any
female subjects. Gender effects thus remain to be examined. Finally, an association between
the occipital lobe and visual hallucinations should be confirmed in a larger sample, since visual
hallucination scores were available in a part of the patients with schizophrenia of the present
study.
In summary, the present study used consistent neuroanatomical boundaries for defining PVA
and VAA, using three-dimensional information from MRI scans. These results suggest that
patients with schizophrenia have relatively intact PVA and reduced bilateral VAA, which may
be the substrate of some of the deficits observed in early visual processing.
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Figure 1.
Delineation of PVA and VAA in occipital lobe. PVA is shown in purple, and VAA is shown
in blue. For the medial surface (left), the border between parietal lobe and occipital lobe is the
parietooccipital sulcus. PVA is defined as the area including one gyrus above and one gyrus
below the calcarine fissure. For the lateral surface (right), the border between the two lobes is
delineated by a guideline connecting the parietooccipital fissure and the superior temporal
sulcus on the most anterior slice of occipital lobe (The guideline is shown in red).
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Figure 2.
Sagittal and coronal MR images showing delineation of PVA and VAA. (a) The rater identifies
the parietooccipital sulcus and the calcarine fissure on the midsaggital plane. (b) The yellow
lines are the guidelines extending the sulcal courses used to delineate PVA and VAA. (c) On
a coronal slice PVA and VAA are delineated by referring to the guidelines (yellow dots). In
part B, here shown as yellow dots. On the lateral surface, the parietal lobe and occipital lobe
are operationally separated by extending the guideline (the red dot) horizontally and medially
across the tissue bridge of white matter horizontally and medially up to the intraparietal sulcus.
(d) A coronal view of PVA and VAA delineation. White matter and gray matter were shown
in light yellow and light blue respectively. The gray matter of PVA is shown in orange (subject
left) and purple (subject right). The gray matter of VAA is shown in red (subject left) and blue
(subject right).
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Figure 3.
Scattergram of PVA and VAA relative volumes on the left and right in patients with
schizophrenia (circles) and normal control subjects (triangles). Means are indicated by
horizontal lines. * Patients showed bilateral VAA reduction compared with normal controls
(F[1,51]=5.05, p=0.03).
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